Date of publication: 22 July 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Moderna for children 6 to continue reading : HTAC Recommendation on COVID-19 Moderna for children 6 to 11 years old
HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
On 19 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of zoledronic acid (4mg/5mL concentrated solution for IV infusion) for the treatment of patients with malignancy-related bone disease through its inclusion in the PNF. In developing its recommendation for zoledronic acid, the HTAC considered the following: Details of continue reading : HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
Evidence brief for 8 to 14 October 2022
For the period of 08 to 14 October 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 08 – 14 October 2022 Document Preview:
HTAC Guidance: Limited evidence of improved protection from 2nd booster dose among healthy individuals aged 18-49 years
On 22 September 2022, the HTAC submitted its findings on 2nd boosters for healthy individuals ages 18 to 49 years to the Office of the Secretary based on the best available evidence using the HTAC decision framework: Evaluation Framework The HTAD received the acceptance of the OIC-SOH of the findings on 2nd booster for healthy individual ages continue reading : HTAC Guidance: Limited evidence of improved protection from 2nd booster dose among healthy individuals aged 18-49 years